Dianthus Therapeutics (DNTH) Total Current Liabilities (2017 - 2025)

Dianthus Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $30.7 million for Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 66.55% year-over-year to $30.7 million in Q4 2025; TTM through Dec 2025 was $30.7 million, a 66.55% increase from a year earlier, with the FY2025 full-year figure at $30.7 million, up 66.55% from the prior year.
• Total Current Liabilities rose to $30.7 million in Q4 2025 per DNTH's latest filing, from $23.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $30.7 million in Q4 2025 and bottomed at $4.0 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $11.2 million (2021), against an average of $13.3 million.
• Across the five-year window, Total Current Liabilities sank 64.16% in 2023 and surged 148.61% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $10.9 million in 2021, then declined by 24.28% to $8.2 million in 2022, then gained by 17.09% to $9.6 million in 2023, then soared by 91.59% to $18.5 million in 2024, then surged by 66.55% to $30.7 million in 2025.
• Per Business Quant, the three latest DNTH Total Current Liabilities figures stand at $30.7 million (Q4 2025), $23.9 million (Q3 2025), and $20.1 million (Q2 2025).